China is moving beyond being just a commercial market to becoming an innovation engine, said Amit Kakar, head of Novo Holdings Asia. ‪As global biopharma companies ramp up local investments to bring Chinese innovative drugs to the world, they are actively capitalizing on the "China Opportunity 2.0".